SCHEDULE 13G/A: Bain Capital Life Sciences Reduces Stake in Annexon, Inc. Below 5% Threshold

Sentiment:

Beneficial Ownership Report 14 February 2025 12:55 PM

Bain Capital Life Sciences Entities have filed an amendment to their Schedule 13G, disclosing a beneficial ownership of 4.9% in Annexon, Inc. as of December 31, 2024, indicating a reduction below the 5% reporting threshold.

Worse than expectedThe filing indicates that Bain Capital Life Sciences' beneficial ownership has fallen below the 5% threshold, suggesting a reduction in their stake. While not explicitly stated as a 'sale', a decrease below the reporting threshold by a major institutional investor like Bain Capital is often viewed negatively by the market, implying a potential lack of continued conviction or a strategic exit.

Summary

Bain Capital Life Sciences Entities, specifically BCLS I Investco, LP, BCIP Life Sciences Associates, LP, and Bain Capital Life Sciences Fund, L.P., filed an Amendment No. 5 to their Schedule 13G.
As of December 31, 2024, BCLS I Investco, LP beneficially owned an aggregate of 5,249,069 shares of Annexon, Inc. Common Stock.
This beneficial ownership represents approximately 4.9% of Annexon, Inc.'s outstanding Common Stock.
The calculation is based on 106,593,505 shares of Common Stock outstanding as of November 11, 2024, plus 774,943 shares issuable upon the exercise of warrants held by BCLS I Investco.
BCLS I Investco held 4,474,126 shares of Common Stock and warrants to purchase 774,943 shares of Common Stock.
The other reporting persons, BCIP Life Sciences Associates, LP and Bain Capital Life Sciences Fund, L.P., reported 0% beneficial ownership.
The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative because a major institutional investor reducing its stake below the 5% reporting threshold can be perceived as a loss of confidence or a strategic divestment, potentially signaling a less favorable outlook for the company from that investor's perspective.

Negatives

The reduction of Bain Capital Life Sciences' beneficial ownership below the 5% threshold could be interpreted by the market as a decrease in conviction or a strategic divestment by a significant institutional investor.

Future Outlook

Industry Context

This filing is a standard disclosure of beneficial ownership by a significant institutional investor in a biotechnology company. Such disclosures provide transparency regarding major shareholders' positions, which can influence market perception of a company's stability and investor confidence.

Stakeholder Impact

Shareholders: The reduction in a significant institutional investor's stake may lead to concerns about the company's future prospects or the investor's long-term commitment, potentially influencing stock price.

Key Dates

Date	Description
2024-11-11	Date as of which 106,593,505 shares of Common Stock were reported as issued and outstanding by Annexon, Inc. in its Quarterly Report on Form 10-Q.
2024-12-31	Date of event which requires filing of this statement, representing the snapshot of beneficial ownership.
2025-02-14	Date the Schedule 13G Amendment No. 5 was filed.

Keywords

Annexon Inc., Bain Capital Life Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.